Related references
Note: Only part of the references are listed.Estimating the Global Burden of Endemic Canine Rabies
Katie Hampson et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model
Lisa Oestereich et al.
ANTIVIRAL RESEARCH (2014)
Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model
Sophie J. Smither et al.
ANTIVIRAL RESEARCH (2014)
Characterization of street rabies virus variants with an additional N-glycan at position 247 in the glycoprotein
Kentaro Yamada et al.
ARCHIVES OF VIROLOGY (2014)
Efficient N-glycosylation at position 37, but not at position 146, in the street rabies virus glycoprotein reduces pathogenicity
Kentaro Yamada et al.
VIRUS RESEARCH (2014)
Current and future approaches to the therapy of human rabies
Alan C. Jackson
ANTIVIRAL RESEARCH (2013)
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Yousuke Furuta et al.
ANTIVIRAL RESEARCH (2013)
Involvement of the Rabies Virus Phosphoprotein Gene in Neuroinvasiveness
Satoko Yamaoka et al.
JOURNAL OF VIROLOGY (2013)
Role of Human Hypoxanthine Guanine Phosphoribosyltransferase in Activation of the Antiviral Agent T-705 (Favipiravir)
Lieve Naesens et al.
MOLECULAR PHARMACOLOGY (2013)
Passive immunity in the prevention of rabies
Leonard Both et al.
LANCET INFECTIOUS DISEASES (2012)
Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: A randomized, dose-escalation phase 1 study in adults
Nithya Gogtay et al.
VACCINE (2012)
Serial passage of a street rabies virus in mouse neuroblastoma cells resulted in attenuation: Potential role of the additional N-glycosylation of a viral glycoprotein in the reduced pathogenicity of street rabies virus
Kentaro Yamada et al.
VIRUS RESEARCH (2012)
Five-year (January 2004-December 2008) surveillance on animal bite and rabies vaccine utilization in the Infectious Disease Hospital, Dhaka, Bangladesh
Moazzem Hossain et al.
VACCINE (2011)
Socioeconomic status is a critical risk factor for human rabies post-exposure prophylaxis
Li Xiao Fang et al.
VACCINE (2010)
Effect of T-705 treatment on western equine encephalitis in a mouse model
Justin G. Julander et al.
ANTIVIRAL RESEARCH (2009)
Development and evaluation of a rapid neutralizing antibody test for rabies
Seiji Shiota et al.
JOURNAL OF VIROLOGICAL METHODS (2009)
Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents
John D. Morrey et al.
ANTIVIRAL RESEARCH (2008)
First administration to humans of a monoclonal antibody cocktail against rabies virus: Safety, tolerability, and neutralizing activity
A. B. H. Bakker et al.
VACCINE (2008)
Brief report - Survival after treatment of rabies with induction of coma
RE Willoughby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
In vitro and in vivo activities of anti-influenza virus compound T-705
Y Furuta et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Share Paper
